Story perspectives

Eli Lilly Unveils TuneLab: Free AI Platform for Biotech Startups

9/10/2025

Summary

Story summary

Eli Lilly launched TuneLab, an AI and machine learning platform for biotech firms, on September 9, 2025.
The platform offers drug discovery models based on over $1 billion of Lilly's research data at no cost to small biotech companies.
Partners enhance AI models by contributing their training data.
TuneLab is part of Lilly's Catalyze360 program, which provides funding and lab space for startups.
Early-stage companies like Insitro and Circle Pharma are collaborating with Lilly, utilizing federated learning to safeguard proprietary data.

History

Historical Context

The 2012 U.S. Supreme Court ruling in Mayo Collaborative Services v. Prometheus Laboratories reshaped patent eligibility for medical diagnostics. Eli Lilly's TuneLab, utilizing over $1 billion in research data, exemplifies a trend towards open collaboration in biotech. By offering free AI tools, Lilly supports startups like Insitro and Circle Pharma, potentially accelerating drug discovery and fostering a competitive biotech environment.

1 of 2

Story summary

Eli Lilly launched TuneLab, an AI and machine learning platform for biotech firms, on September 9, 2025.
The platform offers drug discovery models based on over $1 billion of Lilly's research data at no cost to small biotech companies.
Partners enhance AI models by contributing their training data.
TuneLab is part of Lilly's Catalyze360 program, which provides funding and lab space for startups.
Early-stage companies like Insitro and Circle Pharma are collaborating with Lilly, utilizing federated learning to safeguard proprietary data.

1 / 2